1. Home
  2. CTNM vs ESPR Comparison

CTNM vs ESPR Comparison

Compare CTNM & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • ESPR
  • Stock Information
  • Founded
  • CTNM 2009
  • ESPR 2008
  • Country
  • CTNM United States
  • ESPR United States
  • Employees
  • CTNM N/A
  • ESPR N/A
  • Industry
  • CTNM
  • ESPR Biotechnology: Pharmaceutical Preparations
  • Sector
  • CTNM
  • ESPR Health Care
  • Exchange
  • CTNM Nasdaq
  • ESPR Nasdaq
  • Market Cap
  • CTNM 378.7M
  • ESPR 399.0M
  • IPO Year
  • CTNM 2024
  • ESPR 2013
  • Fundamental
  • Price
  • CTNM $14.14
  • ESPR $2.34
  • Analyst Decision
  • CTNM Strong Buy
  • ESPR Buy
  • Analyst Count
  • CTNM 4
  • ESPR 4
  • Target Price
  • CTNM $29.25
  • ESPR $8.13
  • AVG Volume (30 Days)
  • CTNM 82.5K
  • ESPR 8.7M
  • Earning Date
  • CTNM 11-06-2024
  • ESPR 11-07-2024
  • Dividend Yield
  • CTNM N/A
  • ESPR N/A
  • EPS Growth
  • CTNM N/A
  • ESPR N/A
  • EPS
  • CTNM N/A
  • ESPR N/A
  • Revenue
  • CTNM N/A
  • ESPR $295,451,000.00
  • Revenue This Year
  • CTNM N/A
  • ESPR $186.90
  • Revenue Next Year
  • CTNM N/A
  • ESPR $31.10
  • P/E Ratio
  • CTNM N/A
  • ESPR N/A
  • Revenue Growth
  • CTNM N/A
  • ESPR 187.12
  • 52 Week Low
  • CTNM $12.33
  • ESPR $1.58
  • 52 Week High
  • CTNM $22.00
  • ESPR $3.94
  • Technical
  • Relative Strength Index (RSI)
  • CTNM N/A
  • ESPR 44.07
  • Support Level
  • CTNM N/A
  • ESPR $1.84
  • Resistance Level
  • CTNM N/A
  • ESPR $2.54
  • Average True Range (ATR)
  • CTNM 0.00
  • ESPR 0.43
  • MACD
  • CTNM 0.00
  • ESPR -0.12
  • Stochastic Oscillator
  • CTNM 0.00
  • ESPR 23.57

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Share on Social Networks: